Video
Author(s):
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.